GNOM News and Press, Global X Genomics & Biotechnology ETF From 06/21/19

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...

Array BioPharma is  up 56%  after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is  higher by 8.35%  after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

By Marshall Gordon and Nicholas Wu, PhD Healthcare stocks normally react to political rhetoric, but the speed and magnitude of the recent correction in the sector have been surprising. Despite bipartisan clamoring for broad changes to the healthcare system and the Trump administration'...